ZimVie Inc. (NASDAQ:ZIMV) Stake Lessened by CenterBook Partners LP

CenterBook Partners LP reduced its stake in shares of ZimVie Inc. (NASDAQ:ZIMV - Free Report) by 36.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,496 shares of the company's stock after selling 55,009 shares during the period. CenterBook Partners LP owned 0.35% of ZimVie worth $1,042,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in ZIMV. Wealthquest Corp bought a new stake in ZimVie in the 1st quarter worth approximately $182,000. Wealth Enhancement Advisory Services LLC grew its position in ZimVie by 5.8% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 15,127 shares of the company's stock valued at $211,000 after acquiring an additional 836 shares during the last quarter. Wells Fargo & Company MN grew its position in ZimVie by 17.8% in the 4th quarter. Wells Fargo & Company MN now owns 17,037 shares of the company's stock valued at $238,000 after acquiring an additional 2,569 shares during the last quarter. Integrated Quantitative Investments LLC bought a new position in ZimVie in the 4th quarter valued at $248,000. Finally, Deutsche Bank AG grew its position in ZimVie by 61.7% in the 4th quarter. Deutsche Bank AG now owns 23,796 shares of the company's stock valued at $332,000 after acquiring an additional 9,084 shares during the last quarter. 95.63% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ZIMV. UBS Group decreased their price objective on ZimVie from $16.00 to $10.00 and set a "neutral" rating for the company in a research note on Thursday, May 15th. Wall Street Zen lowered ZimVie from a "strong-buy" rating to a "buy" rating in a report on Friday. Needham & Company LLC reiterated a "hold" rating on shares of ZimVie in a research report on Wednesday, April 9th. Finally, B. Riley started coverage on ZimVie in a report on Thursday, April 10th. They issued a "buy" rating and a $16.00 price objective on the stock.

ZimVie Stock Performance

ZIMV traded down $0.22 on Friday, hitting $8.44. 201,418 shares of the company traded hands, compared to its average volume of 178,376. The company has a 50 day moving average of $9.05 and a 200-day moving average of $10.90. The company has a quick ratio of 1.48, a current ratio of 2.14 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $235.05 million, a PE ratio of -11.89 and a beta of 2.07. ZimVie Inc. has a 12-month low of $8.15 and a 12-month high of $22.18.

ZimVie (NASDAQ:ZIMV - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.06. The company had revenue of $112.00 million during the quarter, compared to the consensus estimate of $113.10 million. ZimVie had a positive return on equity of 5.53% and a negative net margin of 4.40%. Sell-side analysts anticipate that ZimVie Inc. will post 0.6 earnings per share for the current year.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.